Core Insights - Vivos Inc. is preparing to open two new production facilities to enhance its RadioGel Radionuclide Therapy production capabilities [1] Group 1: Production Facilities - The company has been assessing alternate facilities for the past two years due to risks associated with relying on a single production site [2] - Vivos aims to have one domestic production facility and one international production facility operational by 2026, which will produce Y-90 phosphate particles mixed with sterile hydrogel for patient doses [2] - A contract has been signed for production space at the Applied Process Engineering Laboratory (APEL) in Richland, Washington, with manufacturing equipment ordered and installation underway [3] Group 2: International Expansion - The company is in discussions with radiopharmaceutical contract manufacturers in India to establish an international production facility, expected to be operational by the end of 2026 [4] - The international production footprint is anticipated to reduce shipping costs and logistical complexity, thereby expanding access to international markets for both RadioGel and IsoPet therapies [4] Group 3: Future Development - APEL will serve as a cornerstone for the company's automated production development, supporting higher production volumes and long-term expansion [3]

Core Insights - Vivos Inc. is advancing its RadioGel technology, a Precision Radionuclide Therapy (PRnT), and is working towards securing FDA Investigational Device Exemption (IDE) approval for human clinical trials [1][6] Company Efforts - The company has engaged extensively with the FDA, addressing feedback from over 40 reviewers and finalizing key technical parameters to demonstrate the precision delivery of RadioGel [3] - Vivos has hired a top regulatory expert in brachytherapy to enhance its IDE submission, leveraging the expert's experience with successful IDE approvals for similar devices [4] - The company plans to submit the IDE by the end of Q1 or in April, indicating a strong commitment to advancing RadioGel towards human clinical trials [6] Submission Enhancements - The IDE submission will include fully addressing FDA concerns, incorporating new clinical human data, and reformatting pre-clinical data to better meet FDA expectations [8] - The submission will leverage extensive veterinary clinical data from IsoPet, showcasing over 100 safely administered therapies with no serious adverse events, to strengthen the evidence for safety and efficacy [8] - Specialized equine ocular applications will be highlighted, including successful treatments of ocular squamous cell carcinoma in horses, demonstrating the therapy's precision and minimal invasiveness [8]

Core Insights - Vivos Inc. has provided a positive update regarding ongoing human therapy demonstrations in India using RadioGel Precision Radionuclide Therapy, initiated in December 2024 [1] Group 1: Patient Outcomes - Patients have been attending regulatory follow-up visits as per protocol, with no serious adverse events reported to date [2] - Some patients have shown tumor size reduction over short intervals, with no recurrence noted during the follow-up period [3] - The therapy has been evaluated in cases involving tumors near critical structures, with no damage to adjacent organs reported [3] Group 2: Regulatory and Clinical Development - The company is working towards obtaining DCGI regulatory clearance later this quarter to expand the therapy phase, which will include enhanced protocols based on prior FDA interactions [4] - A therapist and facility have been selected for a larger-scale clinical trial to support future regulatory and commercial pathways in India [5] - Vivos Inc. is committed to submitting comprehensive results from the India demonstrations as part of its efforts to share scientific insights with the medical community [6] Group 3: Product Development Focus - Vivos Inc. remains focused on the development of RadioGel as a targeted therapy option for solid tumors, with ongoing support from shareholders [7]

Core Insights - Vivos Inc. is focused on obtaining FDA Investigational Device Exemption (IDE) approval to start human clinical studies at Mayo Clinic, having engaged with over 40 FDA reviewers to address their inquiries [1][3] - The company is preparing a second Pre-Submission to the FDA, targeting high-impact areas identified in previous feedback, which will help streamline the IDE submission process [4][5] - Vivos has established Vivos Scientific India LLP (VISL) to facilitate regulatory approvals and manufacturing in India, aiming to tap into the $2 billion human oncology and $100 million veterinary therapy markets [6][7][8] Regulatory Strategy - The company has hired regulatory expert John Smith to guide its IDE approval process, leveraging his extensive experience with brachytherapy devices [3][5] - A proactive approach is being taken with the second Pre-Submission to address recurring FDA feedback on radiation dosimetry and clinical protocol design [4][5] International Expansion - Vivos is expanding its presence in India with plans for clinical trials and a manufacturing center, which will support both human and veterinary applications of RadioGel [7][8] - The company is also exploring international markets with unmet needs in oncology and veterinary care, aiming to establish a global platform for RadioGel [9][10] Veterinary Market Growth - The IsoPet division has seen an 800% year-over-year increase in administered therapies, indicating strong demand and adoption in the veterinary sector [11] - A strategic partnership with Exubrion Therapeutics aims to promote IsoPet in the equine oncology segment, which presents significant growth opportunities [13] Manufacturing and Technology - Vivos plans to transition from fully outsourced manufacturing to establishing its own production centers, with operations expected to begin in the second quarter of 2026 [14] - The company maintains a comprehensive intellectual property portfolio, including patents and developmental data related to its hydrogel technologies [15]

Core Insights - Vivos Inc. and Exubrion Therapeutics have announced enhanced cooperation to advance targeted radioactive isotope technology for companion animals [1][2] - The collaboration will focus on shared clinic relationships, licensing coordination, and manufacturing optimization, building on previous efforts in device classification and clinician training [2] - Both companies aim to leverage their complementary strengths in treating different conditions in companion animals, with Vivos focusing on cancer therapy and Exubrion on osteoarthritis pain [3] Company Overview - Vivos Inc. is a radiotherapeutic company developing isotope-based products for cancer treatment and other therapeutic applications, including RadioGel for human use and IsoPet for veterinary applications [4] - Exubrion Therapeutics specializes in veterinary radiotherapeutics, with its lead product, Synovetin OA, targeting osteoarthritis in companion animals [5]

Core Points - Vivos Inc. has authorized the formation of a wholly owned subsidiary in India named Vivos Scientific India LLP, and is in the process of obtaining formal approvals from the Indian government [1] - The establishment of the subsidiary reflects Vivos's long-term commitment to the Indian market, aiming to set up its first international manufacturing center for RadioGel and IsoPet, and to expand developmental animal testing and commercial treatments in India [2] - Vivos has initiated first-in-human trials in India and is pursuing additional approvals for expanded human trials from the Drug Controller General of India (DCGI), which are believed to support the IDE process with the FDA [2] Company Strategy - The company plans to include immediate post-treatment PET full-body scans in the next phase of human trials in India to validate the safety profile of RadioGel, based on feedback from the FDA [2]

Core Points - Vivos Inc. has received authorization to establish a wholly owned subsidiary in India named Vivos Scientific India LLP, and is in the process of obtaining formal approvals from the Indian government [1] - The establishment of the subsidiary reflects Vivos Inc.'s long-term commitment to the Indian market, aiming to set up an international manufacturing center for RadioGel and IsoPet, and to expand developmental animal testing and commercial treatments for humans and animals in India [2] - Vivos Inc. has initiated first-in-human trials in India and is pursuing approval from the Drug Controller General of India (DCGI) for expanded human trials, which are expected to support the IDE process with the FDA [2] Company Strategy - The company plans to include immediate post-treatment PET full-body scans in the next phase of human trials in India to validate the safety profile of RadioGel, based on feedback from the FDA [2]

Core Insights - Vivos Inc. reported a record-breaking first quarter for its IsoPet Animal Cancer Division, with a 150% year-over-year increase in treatment volume, highlighting its growing role in veterinary oncology [1][2] Group 1: Treatment Volume Surge - IsoPet treated 15 pets in Q1 2025, a 150% increase from Q1 2024, with a biweekly production schedule ensuring a steady supply of yttrium-90 (Y-90) hydrogel for targeted radiation [2] - Recent treatments included five pets in New Jersey and Texas, demonstrating the therapy's effectiveness in reducing tumors and improving quality of life [2] Group 2: Breakthrough Clinical Applications - IsoPet made significant advancements in equine oncology, treating four horses with ocular squamous cell carcinoma using direct cornea injections, a novel approach for this challenging condition [3] - Additional applications include palliative therapy for advanced equine jaw cancer and margin therapy post-tumor resection [3] Group 3: Clinic Expansion - Vivos Inc. activated three new certified clinics in Q1 2025, increasing the total to 14 clinics, with plans for further expansion to enhance access for pet owners [4] - The new clinics include specialized facilities for both small animals and equines, emphasizing the importance of trained veterinarians in the success of IsoPet [4] Group 4: Strategic Marketing and Community Engagement - IsoPet increased its presence at major veterinary conferences and utilized targeted newsletters and social media to drive treatment inquiries and community support [5] - Positive feedback from pet owners on social media highlights the effectiveness of IsoPet's non-surgical approach [5] Group 5: Market Positioning - The global veterinary oncology market, valued at $1.18 billion in 2023, is projected to grow at an 11.3% CAGR through 2030, driven by rising cancer diagnoses in pets [6] - IsoPet's minimally invasive therapy is well-positioned to meet this growing demand, offering a cost-competitive alternative to traditional radiation [6] Group 6: Leadership Perspective - The President & CEO of Vivos Inc. emphasized the transformative impact of IsoPet on veterinary oncology and the commitment to expanding access and exploring new applications [7][8]

Core Insights - Vivos Inc. is advancing its human clinical trial for RadioGel Precision Radionuclide Therapy in India, which is designated as a Breakthrough Device by the FDA for treating solid tumors [1][10] Clinical Progress - The trial has successfully treated ten patients, confirming a strong safety profile and early evidence of efficacy, building on initial results that confirmed safety in the first five patients [2][3] - All patients have met the primary safety endpoint, with PET imaging showing precise retention of Yttrium-90 isotope at the injection site and no adverse events reported [3] - RadioGel has successfully treated tumors in high-risk anatomical regions without damaging adjacent critical tissues, demonstrating a high Therapeutic Ratio [4] Technical Innovations - The clinical team has implemented new technical refinements, including deep-needle injection techniques and precision image guidance, enhancing dose control and organ protection [6] - Ongoing discussions with Mayo Clinic investigators are aimed at preparing for a parallel clinical study in the U.S. [6] Expansion Plans - The study in India is approved to treat 30 patients, with a request being prepared to increase this to 50 patients to evaluate RadioGel in a broader range of tumor types [7] - Vivos is establishing a permanent operational presence in India, including plans for a corporate office and a regional manufacturing facility for yttrium phosphate microparticles [8] Market Opportunity - The cancer treatment market in India was valued at approximately USD 4.21 billion in 2023 and is projected to reach USD 5.89 billion by 2030, presenting a significant opportunity for innovative therapies like RadioGel [12] - Establishing a presence in India allows Vivos to diversify revenue streams and enhance global recognition of RadioGel as a relevant oncology solution [12] Regulatory Strategy - Vivos is sharing preliminary trial data with the FDA to support an Investigational Device Exemption (IDE) submission within the next 90 days [10] - The company is pursuing a multi-track global strategy to ensure momentum in regulatory progress, particularly in regions with streamlined pathways for innovative cancer therapies [10][11]